Skip to main content

Fiscal Wizard · Single-issue tearsheet

MCK / Aug 13, 2026 Run #13848

MCK

McKesson Corporation

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Composite verdict

D 40.3 / 100
Gated stand-aside 0 drivers · 4 gates blocking
Stand aside Setup or conviction grade does not support a directional trade.

Industry rank 1st of 4 in Medical Distribution

rescore-sweep
Technical synthesisRegime: volatile uptrend

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from
Asset value $-18.63Earnings power value $475.79Price $878.73

Priced above its no-growth earnings power value ($475.79/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

40.3 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Operating Margin 0
EPS Growth (YoY) 100
Net Margin 0
Asset Turnover 100
Gross Margin 0

Technicals Unscored

/ 100

Stand aside — active guards gated the directional signals that fired. · 44 signals shown.

Risk Gates

4 blocking 4 caution

4 guards active, 44 signals gated.

Earnings Event Blackout Blocking

Mutes all technical signals within the earnings announcement window when earnings dates are available.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for MCK.